Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

IU Health Advanced Therapies Pharmacy

Alecensa

Alunbrig

Ayvakit

Besremi

Bosulif

Braftovi

Brukinsa

Cabometyx

Calquence

Cometriq

Copiktra

Cotellic

Daurismo

Erleada

Erivedge

Fotivda

Gavreto

Gilotrif

Ibrance

Iclusig

Idhifa

Imbruvica

Inlyta

Inqovi

Inrebic

Iressa

Jakafi

Koselugo

Lenvima

Lonsurf

Lorebrena

Lumakras

Lynparza

Matulane

Mekinist

Mektovi

Nerlynx

Nubeqa

Odomzo

Onureg

Orgovyx

Piqray

Qinlock

Retevmo

Revlimid

Rozlytrek

Rubraca

Stivarga

Tabrecta

Tafinlar

Tagrisso

Talzenna

Tasigna

Tibsovo

Trelsat

Truseltiq

Tukysa

Venclexta

Verenzio

Vitravki

Vizimpro

Vonjo

Votrient

Xalkori

Xospata

Xpovio

Xtandi

Zejula

Zelboraf

Zydelig

Zykadia

Zytiga

Rinvoq | IU Health Advanced Therapies Pharmacy

Which health plans does IU Health Advanced Therapies Pharmacy have contracts with?

Does IU Health Advanced Therapies Pharmacy offer services for Rinvoq patients?

What conditions does IU Health Advanced Therapies Pharmacy support?

How does IU Health Advanced Therapies Pharmacy help with insurance?